Lindahl advises Corline Biomedical AB on directed share issue

Lindahl is acting as legal adviser to Corline Biomedical AB (publ) in connection with a directed share issue amounting to approximately SEK 23 million.

Through the share issue, Corline Biomedical will receive approximately SEK 23 million before deduction of issue costs. In addition, the company strengthens its shareholder base with a long-term and international investor, Eiffel Investment Group, to which the issue is directed.

Corline Biomedical develops and sells medical technology solutions. The company's shares are listed on Nasdaq First North Growth Market.

Lindahl's team consists of Mattias Prage and Olle Swärd Brattström.

Do you want to know more? Contact:

Mattias Prage

Partner | Advokat

Olle Swärd Brattström

Associate